Compare RANI & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | LNSR |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 146.7M |
| IPO Year | 2021 | 2005 |
| Metric | RANI | LNSR |
|---|---|---|
| Price | $1.37 | $12.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $8.60 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 804.8K | 40.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.05 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,028,000.00 | ★ $53,494,000.00 |
| Revenue This Year | $414.59 | $19.55 |
| Revenue Next Year | $30.15 | $35.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.87 |
| 52 Week Low | $0.39 | $9.46 |
| 52 Week High | $3.87 | $17.31 |
| Indicator | RANI | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 50.77 |
| Support Level | $1.31 | $11.85 |
| Resistance Level | $1.42 | $12.80 |
| Average True Range (ATR) | 0.08 | 0.40 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 80.95 | 65.25 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.